Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Triple needle** is an investigational intra-articular treatment regimen for early and mid-stage knee osteoarthritis consisting of betamethasone, lidocaine, and sodium hyaluronate. In the registered ChiCTR2100048131 study, the initial injection contained 0.3 mL betamethasone, 0.7 mL lidocaine, and 2 mL sodium hyaluronate, followed by four weekly sodium hyaluronate injections. Betamethasone provides local glucocorticoid anti-inflammatory activity, lidocaine provides rapid local analgesia through neuronal sodium-channel blockade, and sodium hyaluronate provides intra-articular viscosupplementation. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12971529/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triple needle.